Ab therapy of AML: native anti-CD33 Ab and drug conjugates

ISSN： 1465-3249

Source： Cytotherapy, Vol.10, Iss.1, 2007-10, pp. : 7-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primitive AML progenitors from most CD34+ patients lack CD33 expression but progenitors from many CD34- AML patients express CD33

By Vercauteren Sm Zapf R. Sutherland Hj

Cytotherapy, Vol. 9, Iss. 2, 2007-01 ,pp. : 194-204

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy

Cytometry. Part B: Clinical Cytometry, Vol. 94, Iss. 1, 2018-01 ,pp. : 112-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Repression of transfusion-related acute lung injury: role of anti-cytokine and anti-chemokine Ab

By Nishimura M.

Cytotherapy, Vol. 9, Iss. 6, 2007-01 ,pp. : 577-579

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Immune therapy of AML

By Molldrem J

Cytotherapy, Vol. 4, Iss. 5, 2002-09 ,pp. : 437-438

Ashgate Publishing Ltd

Access to resources Recommend Favorite

CML leukapheresis products can be enriched for CD34⁺ cells and simultaneously depleted of CD15⁺ cells using a simple Ab cocktail

By Richmond LJ Alcorn MJ Pearson C Cameron G Thomas T Eaves CJ Eaves AC Holyoake TL

Cytotherapy, Vol. 4, Iss. 5, 2002-09 ,pp. : 407-413

Ashgate Publishing Ltd

Access to resources Recommend Favorite